Downregulation of Hepatic Carbonyl Reductase Type 1 in End-Stage Renal Disease

Publisher： Bentham Science Publishers

E-ISSN： 1874-0758|9|2|111-118

ISSN： 1872-3128

Source： Drug Metabolism Letters, Vol.9, Iss.2, 2015-08, pp. : 111-118

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Epidemiology of end-stage renal disease

By Roderick Paul  

Clinical Medicine, Vol. 2, Iss. 3, 2002-05 ,pp. : 200-204

Royal College Of Physicians

Access to resources Recommend Favorite

Anorexia in end-stage renal disease: pathophysiology and treatment

By Alvarez Vicente   Diéz Juan Jose   Aguilera Abelardo   Selgas Rafael   Codoceo Rosa   Bajo Maria A  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 11, 2001-11 ,pp. : 1825-1838

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics of Rosiglitazone in Patients with End-stage Renal Disease

By Thompson-Culkin K   Zussman B   Miller AK   Freed MI  

The Journal of International Medical Research, Vol. 30, Iss. 4, 2002-07 ,pp. : 391-399

Field House Publishing

Access to resources Recommend Favorite

Approach to the management of end-stage renal disease

By Rodger R Stuart C  

Clinical Medicine, Vol. 12, Iss. 5, 2012-10 ,pp. : 472-475

Royal College Of Physicians

Access to resources Recommend Favorite

End-stage renal disease onset a costly event

By  

Inpharma, Vol. 1, Iss. 1473, 2005-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite